



BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 5, 2026

RESEARCH TRIANGLE PARK, N.C., Feb. 05, 2026 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 24 newly-hired employees stock options to purchase an aggregate of 251,150 shares, and restricted stock units (RSUs) covering an aggregate of 368,550 shares, of BioCryst common stock. The options and RSUs were granted as of February 2, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price of \$6.63 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema ("HAE") and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of potential first-in-class or best-in-class oral small-molecule and injectable protein therapeutics for a range of rare diseases. For more information, please visit www.biocryst.com or follow us on [LinkedIn](#).

BCRXW

Contact:

Investors:

investorrelations@biocryst.com

Media:

media@biocryst.com